Synaptogenix forms special committee to explore strategic alternatives; ends Bryostatin-1 MS trial

TAO Synergies Inc.

Board formed special committee to explore strategic opportunities; $19.6M cash and ~1.3M shares outstanding as of Sept 30, 2024.
Terminated Phase 1 trial of Bryostatin-1 in multiple sclerosis due to slow enrollment.
CEO Alan Tuchman's base salary reduced to $12,500/month effective Jan 1, 2025.
President/CSO Daniel Alkon consulting fee reduced to $16,000/month under new agreement.
Company expects dramatic cash burn decline; submitted NIH grant proposal for Bryostatin-1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.